BOTHELL, Wash., Nov. 16, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"), today announced that it has been named to the Deloitte 2015 Technology Fast 500, an annual ranking of the fastest growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors.
Mike Rice, BioLife's President & CEO, said, "We are honored to receive this recognition by Deloitte and to be included with the elite fastest growing companies in North America. Our portfolio of leading edge biopreservation tools for cells, tissues, and organs are making significant improvements in the manufacturing, distribution, and patient administration of biologic based medicine. With numerous marquee customers using CryoStor® and HypoThermosol® in the biobanking, drug discovery, and regenerative medicine markets, we have the potential for sustained growth over the next several years."
BioLife recently entered the cloud computing space with the commercial launch of its biologistex™ SaaS cold chain management offering, utilizing the award winning evo™ Smart Shipper, a revolutionary high performance thermal shipping container with embedded payload monitoring and GPS tracking technologies.
"Amid a fierce business climate, there seems to be no shortage of new and established companies that are unlocking a seemingly unlimited potential for growth and advancement through technology's continued disruption and proliferation across industries," said Sandra Shirai, principal, Deloitte Consulting LLP and U.S. technology, media and telecommunications leader. "It is inspiring to witness the innovative ways that companies are incorporating emerging technologies for business gains, be it cognitive computing, or the Internet of Things. We congratulate all those ranked on this year's Fast 500 and look forward to seeing their continued growth into 2016."
About Deloitte's 2015 Technology Fast 500™ Deloitte's Technology Fast 500 provides a ranking of the fastest growing technology, media, telecommunications, life sciences and energy tech companies – both public and private – in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2011 to 2014.
In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company's operating revenues. Companies must have base-year operating revenues of at least $50,000 USD or CD, and current-year operating revenues of at least $5 million USD or CD. Additionally, companies must be in business for a minimum of five years and be headquartered within North America.
About BioLife Solutions BioLife Solutions develops, manufactures and markets hypothermic storage and cryopreservation solutions and smart shipping containers connected to a cloud hosted cold chain management app to improve the quality of delivery logistics for cells, tissues, and organs. BioLife also performs contract aseptic media formulation, fill, and finish services. The Company's proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. BioLife's enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs. For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.
This press release contains forward-looking statements, including, but not limited to, statements concerning new products, the company's anticipated business and operations, the potential utility of and market for its products and services, potential revenue growth and market expansion, and, projected financial results and liquidity. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding market adoption of products; uncertainty regarding third party market projections; market volatility; competition; litigation; and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.
Media & Investor Relations Daphne Taylor Senior Vice President, Chief Financial Officer (425) 402-1400 email@example.com
SOURCE BioLife Solutions, Inc.